Results Of A Phase I/Ii Multicenter Trial Of Galiximab (Idec-114, Anti-Cd80 Antibody) Therapy For Relapsed Or Refractory Follicular Lymphoma.
BLOOD(2003)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined